German pharma major Bayer has announced the start of its Phase III study SUNFLOWER, an investigational study evaluating the ...

Bayer initiates phase III study SUNFLOWER with long-acting reversible intrauterine system for treatment of nonatypical endometrial hyperplasia: Berlin Wednesday, December 3, 2025, ...

Bayer (BAYRY) announced the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and safety of 52mg ...

Ontada®, a McKesson business dedicated to real-world oncology data and insights, will present findings from a retrospective cohort study at the 67th American Society of Hematology (ASH) Annual Meeting ...

Bayer announced today the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and safety ...

Orsini, a leader in rare disease pharmacy solutions, announced today that it is a specialty pharmacy partner for ITVISMA® (onasemnogene abeparvovec-brve), an FDA-approved intrathecal gene therapy for ...

Bayer has started a phase 3 trial of its intrauterine contraceptive Mirena in an endometrial condition that can lead to ...

Berlin: Bayer has announced the clinical Phase III study SUNFLOWER with its 52mg levonorgestrel-releasing intrauterine system ...

The role of biomechanical cues in the progression of PM2.5-induced corneal disease was investigated, and PAI-2 was identified ...

CARE Hospitals is a part of Quality Care India Ltd. (QCIL), backed by Blackstone, with the vision to become the largest hospital chain in India through continuous investments in Talent, Technology, ...

Sophia Harris first got on birth control pills at age 10 to manage “out of control” hormone fluctuations. Harris, 27, stayed ...